microRNAs in the Diagnosis of Atherosclerotic Plaque Instability

Atherosclerosis of Artery Clinical Trial

Official title:

The Importance of Determining the Expression Level of Various microRNAs in the Diagnosis of Atherosclerotic Plaque Instability

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05680935
• Other study ID #: 132578
• Status: Recruiting
• Phase: N/A
• Start date: September 5, 2022
• Est. completion date: August 31, 2024

Study information

• Verified date: December 2022
• Source: I.M. Sechenov First Moscow State Medical University
• Contact: Philipp Kopylov, yes
• Phone: +79036877264
• Email: kopylov_f_yu[@]staff.sechenov.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It's a non-randomized, intervention, prospective, single-center study.

The aim of the work is to identify of biomarkers of unstable atherosclerosis in brachiocephalic arteries

Tasks:

• identify microRNAs, the expression of which is characteristic of unstable atherosclerotic lesions;

• to assess the relationship of miRNA and trimethylamine N-oxide with the progression of unstable atherosclerotic lesions;

• to determine the effect of the level of plasma trimethylamine N-oxide on the progression of atherosclerotic lesions.

Description:

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries and up to 30 people - the control group without brachiocephalic atherosclerosis.

As part of the standard of medical care, the patient has already undergone and received the results of the following examinations before being included in the study:

• general clinical laboratory tests (complete blood count, urinalysis, low density lipoproteins, very low density lipoproteins, high density lipoproteins, total cholesterol, triglycerides, total protein, alanine aminotransferase, aspartate aminotransferase, creatinine, urea, glucose)

• ultrasound and/or multislice computed tomography (MSCT) of brachiocephalic arteries.

Patients with clinically significant atherosclerosis of the brachiocephalic arteries were hospitalized for an operation - carotid endarterectomy with obtaining surgical material (atherosclerotic plaque with adjacent intima).

Specific methods of the planned study (procedures for examination and treatment of the patient):

1. In addition, all patients will take blood (20 ml) from the cubital vein to isolate microRNAs and determine the plasma content of trimethylamine N-oxide (TMAO). The resulting surgical material will be sent for histological examination and microRNA isolation.

2. The following statistical data processing methods will be used: frequency distribution, arithmetic mean, mode, median, standard deviation, determination of normal distribution, Student's t-test, Pearson's test, Fisher's test, Spearman's correlation coefficient, multiple linear regression.

During the operation according to the standard protocol of carotid endarterectomy, an atherosclerotic plaque with a small area of adjacent intima is removed. An atherosclerotic plaque obtained during a carotid endarterectomy will be sent for histological examination to determine signs of instability. The obtained data will be compared with the level of isolated microRNAs in blood and tissue (atherosclerotic plaque, intima) to detect microRNAs, which are determined during an unstable course of the atherosclerotic process.

The data obtained will make it possible to predict the unstable course of atherosclerosis using non-invasive studies. This will allow timely detection of unstable plaques and help to make a decision and determine the tactics of managing patients with borderline sizes of atherosclerotic lesions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Availability of written informed consent to participate in research work;

2. Age from 18 to 85 years;

3. Availability of data from a general blood test, blood lipid profile (total cholesterol, very low density lipoproteins, low density lipoproteins, high density lipoproteins, triglycerides);

4. Absence of clinical signs of atherosclerosis of brachiocephalic arteries (no stroke, transient ischemic attack. On auscultation of the carotid arteries, there are no additional noises);

5. Absence of signs of atherosclerosis of the brachiocephalic arteries according to ultrasound duplex scanning (USDS) and/or multispiral computed tomography (MSCT) angiography of the brachiocephalic arteries;

6. Conducted outpatient visit at a research center with clinical and biochemical blood tests performed, ultrasound examination of arterial vessels and/or multispiral tomography of arterial vessels with contrast enhancement and/or hospitalization at a research center.

Non-inclusion criteria:

1. Chronic kidney disease stage 3b and above (glomerular filtration rate < 45 ml / min / 1.73 sq.m);

2. The presence of severe somatic pathology (with the exception of atherosclerosis of the carotid arteries and conditions caused by it), reducing life expectancy to less than 6 months;

3. Chronic somatic diseases in the acute stage;

4. Weight less than 40kg and more than 125kg;

5. Pregnancy.

Exclusion Criteria

1. Refusal to continue participation in the study.

Related Conditions & MeSH terms

• Atherosclerosis
• Atherosclerosis of Artery
• Plaque, Atherosclerotic

Intervention

Diagnostic Test:
• blood microRNA
all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
• plaque and intima microRNA
The resulting surgical material will be sent for microRNA isolation.
• histological examination of the plaque
The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
• blood level trimethyl N-oxide
all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Locations

Country	Name	City	State
Russian Federation	I.M. Sechenov First Moscow State Medical University (Sechenov University)	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
I.M. Sechenov First Moscow State Medical University

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	blood microRNA	blood sampling from the cubital vein 20.0 ml before surgery; centrifuge ethylenediaminetetraacetic acid (EDTA) tubes with blood (ELMI centrifuge, Centrifuge model CM-6M) once at 1000 g for 10 minutes to sediment the cells; select from above ¾ of the plasma volume, so as not to capture cells, into a new empty tube; centrifuge the plasma at 2500 g for 15 minutes to sediment platelets. Remove ¾ of the supernatant without touching the pellet and transfer to a new tube. Repeat the procedure again; Aliquot the supernatant taken a second time into 1.0 ml Eppendorf tubes.; Freeze (Thermo Scientific refrigerator-freezer) and store at -70°C, -80°C.	at study entry, before carotid endarterectomy.
Primary	plaque microRNA	- after receiving an atherosclerotic plaque and adjacent intima during the operation of carotid endarterectomy The atherosclerotic plaque obtained during the surgical intervention (carotid endarterectomy) is cut in half, the adjacent part of the intima is cut off. One half of the plaque is placed in a tube with 10% neutral buffered formalin solution and sent for histological examination. The second half and intima are placed in different test tubes with RNAprotect Tissue Reagent (Qiagen), cooled at +2 °? +4 °?, then frozen (Thermo Scientific refrigerator-freezer) and stored at -70°?, -80°?.	immediately after carotid endarterectomy
Primary	blood TMAO	blood sampling from the cubital vein 20.0 ml before surgery; centrifuge the ethylenediaminetetraacetic acid (EDTA) tube with blood (ELMI centrifuge, Centrifuge model CM-6M) at 2300 g for 15 minutes; take 1.0 ml from the obtained plasma into 2 Eppendorf tubes; Freeze (Thermo Scientific refrigerator-freezer) and store at -70°C, -80°C.	at study entry, before carotid endarterectomy
Primary	histological examination of atherosclerotic plaque	- after receiving an atherosclerotic plaque and adjacent intima during the operation of carotid endarterectomy The atherosclerotic plaque obtained during the surgical intervention (carotid endarterectomy) is cut in half, the adjacent part of the intima is cut off. One half of the plaque is placed in a tube with 10% neutral buffered formalin solution and sent for histological examination.	immediately after carotid endarterectomy
Primary	intima microRNA	after receiving an atherosclerotic plaque and adjacent intima during the operation of carotid endarterectomy; the intima obtained during the surgical intervention (carotid endarterectomy) is placed in a tube with RNAprotect Tissue Reagent (Qiagen), cooled at +2 °? +4 °?, then frozen (Thermo Scientific refrigerator-freezer) and stored at -70°?, -80°?.	immediately after carotid endarterectomy

External Links

•   Assessing the dynamics of vulnerability of atherosclerotic plaques in patients on atorvastatin therapy based on coronary computed tomography angiography (CCTA) data.
•   Multislice Computed Tomography Capabilities in Assessment of the Coronary Arteries Atherosclerotic Lesions.